PL2464382T3 - Leczenie skojarzone z zastosowaniem zdefukozylowanego przeciwciała anty-CD20 i bendamustyny - Google Patents

Leczenie skojarzone z zastosowaniem zdefukozylowanego przeciwciała anty-CD20 i bendamustyny

Info

Publication number
PL2464382T3
PL2464382T3 PL10747168T PL10747168T PL2464382T3 PL 2464382 T3 PL2464382 T3 PL 2464382T3 PL 10747168 T PL10747168 T PL 10747168T PL 10747168 T PL10747168 T PL 10747168T PL 2464382 T3 PL2464382 T3 PL 2464382T3
Authority
PL
Poland
Prior art keywords
afucosylated
bendamustine
antibody
combination therapy
therapy
Prior art date
Application number
PL10747168T
Other languages
English (en)
Polish (pl)
Inventor
Frank Herting
Christian Klein
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2464382(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of PL2464382T3 publication Critical patent/PL2464382T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10747168T 2009-08-14 2010-08-12 Leczenie skojarzone z zastosowaniem zdefukozylowanego przeciwciała anty-CD20 i bendamustyny PL2464382T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09010489 2009-08-14

Publications (1)

Publication Number Publication Date
PL2464382T3 true PL2464382T3 (pl) 2017-09-29

Family

ID=41351729

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10747168T PL2464382T3 (pl) 2009-08-14 2010-08-12 Leczenie skojarzone z zastosowaniem zdefukozylowanego przeciwciała anty-CD20 i bendamustyny

Country Status (34)

Country Link
US (4) US20110165151A1 (es)
EP (1) EP2464382B1 (es)
JP (3) JP5646626B2 (es)
KR (1) KR101425736B1 (es)
CN (2) CN102596245A (es)
AR (1) AR077866A1 (es)
AU (1) AU2010281866B2 (es)
CA (1) CA2769674C (es)
CL (1) CL2012000391A1 (es)
CR (1) CR20120036A (es)
CY (2) CY1119251T1 (es)
DK (1) DK2464382T3 (es)
ES (1) ES2630158T3 (es)
HK (1) HK1245145A1 (es)
HR (1) HRP20170972T1 (es)
HU (2) HUE033531T2 (es)
IL (1) IL217753A (es)
LT (2) LT2464382T (es)
LU (1) LUC00045I2 (es)
MA (1) MA33469B1 (es)
MX (2) MX2012001782A (es)
MY (1) MY163003A (es)
NO (1) NO2017054I1 (es)
NZ (1) NZ597666A (es)
PL (1) PL2464382T3 (es)
PT (1) PT2464382T (es)
RS (1) RS56146B1 (es)
SG (1) SG178324A1 (es)
SI (1) SI2464382T1 (es)
SM (1) SMT201700329T1 (es)
TW (1) TWI409079B (es)
UA (1) UA110096C2 (es)
WO (1) WO2011018224A1 (es)
ZA (1) ZA201200830B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
FR2976811A1 (fr) * 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
CA2841738C (en) * 2011-08-16 2022-12-06 Morphosys Ag Combination therapy with an anti-cd19 antibody and a purine analog
SG10201606785UA (en) * 2011-08-16 2016-10-28 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
CN103375132A (zh) * 2012-04-24 2013-10-30 长江大学 井下旋转冲击式钻井工具
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
BR112015030457A2 (pt) 2013-06-07 2017-08-22 Nordic Nanovector As Método para regular positivamente a expressão de antígeno
WO2015146159A1 (en) 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
CA2979671C (en) 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
JP6750613B2 (ja) 2015-04-09 2020-09-02 小野薬品工業株式会社 プリノン誘導体の製造方法
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
PL3796912T3 (pl) 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
JP7287048B2 (ja) 2019-03-27 2023-06-06 セイコーエプソン株式会社 ロボット
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2023091887A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
AU4079999A (en) 1998-05-15 1999-12-06 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
KR20060012622A (ko) * 2003-05-16 2006-02-08 하이브리돈, 인코포레이티드 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
US20050054048A1 (en) 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
CA2605697A1 (en) 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
ES2642787T3 (es) * 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
EP2234641B1 (en) * 2008-01-03 2015-08-19 Genmab A/S Monoclonal antibodies against cd32b
EA201170940A1 (ru) * 2009-01-16 2012-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
ES2578632T3 (es) * 2009-04-15 2016-07-28 Invista Technologies S.À.R.L. Mejora de la Miscibilidad de compuestos inmiscibles de otro modo

Also Published As

Publication number Publication date
BR112012002855A2 (pt) 2016-11-01
JP5963013B2 (ja) 2016-08-03
NO2017054I1 (no) 2017-10-26
CN107261138A (zh) 2017-10-20
CL2012000391A1 (es) 2012-08-24
IL217753A (en) 2016-10-31
EP2464382B1 (en) 2017-05-03
IL217753A0 (en) 2012-03-29
RS56146B1 (sr) 2017-11-30
SI2464382T1 (sl) 2017-08-31
US20110165151A1 (en) 2011-07-07
HRP20170972T1 (hr) 2017-09-22
UA110096C2 (uk) 2015-11-25
RU2012109445A (ru) 2013-09-27
KR20120054068A (ko) 2012-05-29
TW201110980A (en) 2011-04-01
JP2016222673A (ja) 2016-12-28
NZ597666A (en) 2013-10-25
JP2013501740A (ja) 2013-01-17
HUS000498I2 (hu) 2021-03-29
US20150093376A1 (en) 2015-04-02
CY1119251T1 (el) 2018-02-14
AR077866A1 (es) 2011-09-28
US20140044705A1 (en) 2014-02-13
MY163003A (en) 2017-07-31
SMT201700329T1 (it) 2017-09-07
WO2011018224A1 (en) 2011-02-17
ZA201200830B (en) 2012-10-31
MX2012001782A (es) 2012-04-19
HUS1700041I1 (hu) 2017-11-28
LUC00045I1 (es) 2017-11-03
MA33469B1 (fr) 2012-07-03
CY2017034I2 (el) 2018-02-14
PT2464382T (pt) 2017-06-30
LUC00045I2 (es) 2018-02-26
EP2464382A1 (en) 2012-06-20
CR20120036A (es) 2012-04-18
AU2010281866A1 (en) 2012-02-02
LTPA2017035I1 (lt) 2017-11-27
KR101425736B1 (ko) 2014-08-01
HUE033531T2 (hu) 2021-12-28
LT2464382T (lt) 2017-07-25
AU2010281866B2 (en) 2016-05-12
MX355849B (es) 2018-05-02
CY2017034I1 (el) 2018-02-14
US20120315268A1 (en) 2012-12-13
ES2630158T3 (es) 2017-08-18
HK1245145A1 (zh) 2018-08-24
CA2769674C (en) 2018-01-23
TWI409079B (zh) 2013-09-21
SG178324A1 (en) 2012-03-29
CA2769674A1 (en) 2011-02-17
JP5646626B2 (ja) 2014-12-24
CN102596245A (zh) 2012-07-18
DK2464382T3 (en) 2017-07-17
JP2015071611A (ja) 2015-04-16
US20160166688A9 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
ZA201200830B (en) Combination therapy of an afucosylated cd20 antibody with bendamustine
HRP20190554T1 (hr) Kombinacijska terapija s protutumorskim antibiotikom
EP2405937A4 (en) CANCER THERAPY USING A COMBINATION OF BENDAMUSTIN AND AN ANTIBODY AGAINST CD20
EP2422846A4 (en) CORPUSCULAR RADIATION THERAPY APPARATUS
PL2440287T3 (pl) Urządzenie do terapii fotodynamicznej
IL218724A0 (en) Endoglin antibodies
GB0916666D0 (en) Photodynamic therapy device
EP2618133A4 (en) OPTICAL-ELECTRIC FIELD REINFORCING DEVICE
ZA201103790B (en) Solid dosage forms of bendamustine
ZA201201038B (en) Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
IL215481A0 (en) Improved glucocorticoid therapy
GB0905972D0 (en) Antibodies against IL-17BR
GB2471750B (en) Radiation therapy device
DK2325510T3 (da) Kobling med en ringformet koblingskrop
PL2100692T3 (pl) Sposób wytwarzania urządzenia obróbkowego z korpusem z betonu
GB0902916D0 (en) Antibody therapy
GB201008945D0 (en) An injector
GB0907571D0 (en) The reason of all cancer types
TWM385713U (en) Light source body structure
GB0921244D0 (en) Therapy
GB0914820D0 (en) WATerian therapy
GB0903319D0 (en) Therapy
GB0903321D0 (en) Therapy